MediciNova to Begin Clinical Trial of MN-166 (ibudilast) in ALS

MediciNova, a publicly-traded biopharmaceutical company based in La Jolla, California, has obtained FDA approval to initiate a clinical trial of MN-166 (ibudilast) for the treatment of ALS. MN-166 is a first-in-class, orally bioavailable, small molecule with anti-inflammatory and neuroprotective properties. The drug has been on the market since 1989 in Japan and Korea for treatment of cerebrovascular disorders, and was licensed by MediciNova for use in neurological disorders. The clinical trial will test safety and tolerability of MN-166 vs. placebo when taken in combination with riluzole, as well as assess several efficacy endpoints.

Click here to read more.

Share this: